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Abstract
Background: Airway clearance is frequently needed by patients suffering from blunt chest wall
trauma. High Frequency Chest Wall Oscillation (HFCWO) has been shown to be effective in
helping to clear secretions from the lungs of patients with cystic fibrosis, bronchiectasis, asthma,
primary ciliary dyskinesia, emphysema, COPD, and many others. Chest wall trauma patients are at
increased risk for development of pulmonary complications related to airway clearance. These
patients frequently have chest tubes, drains, catheters, etc. which could become dislodged during
HFCWO. This prospective observational study was conducted to determine if HFCWO
treatment, as provided by The Vest™ Airway Clearance System (Hill-Rom, Saint Paul, MN), was
safe and well tolerated by these patients.
Methods: Twenty-five blunt thoracic trauma patients were entered into the study. These patients
were consented. Each patient was prescribed 2, 15 minute HFCWO treatments per day using The
Vest® Airway Clearance System (Hill-Rom, Inc., St Paul, MN). The Vest® system was set to a
frequency of 10–12 Hz and a pressure of 2–3 (arbitrary unit). Physiological parameters were
measured before, during, and after treatment. Patients were free to refuse or terminate a
treatment early for any reason.
Results: No chest tubes, lines, drains or catheters were dislodged as a result of treatment. One
patient with flail chest had a chest tube placed after one treatment due to increasing serous
effusion. No treatments were missed and continued without further incident. Post treatment
survey showed 76% experienced mild or no pain and more productive cough. Thirty days after
discharge there were no deaths or hospital re-admissions.
Conclusion: This study suggests that HFCWO treatment is safe for trauma patients with lung and
chest wall injuries. These findings support further work to demonstrate the airway clearance
benefits of HFCWO treatment.
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Background
Blunt thoracic trauma can result in a variety of bony and
non-bony injuries [1]. These patients are often cared for in
the intensive care unit (ICU), and frequently require some
form of pulmonary support. Mechanical ventilation car-
ries with it risk for additional complications such as atel-
ectasis and ventilator associated pneumonia (VAP).
Patients requiring intubation often require longer ICU
stays [2]. Avoiding mechanical ventilatory support of
patients who don't absolutely require it results in a better
outcome for these patients [3]. Blunt thoracic trauma
patients and patients with flail chest have been treated
effectively with bilevel positive pressure (BiPAP), contin-
uous positive airway pressure (CPAP), or intermittent
positive pressure ventilation (IPPV), with improved out-
comes resulting from BiPAP and CPAP [2,4]. A recent
study of mucociliary clearance in ICU patients demon-
strated a significant deficit in clearance ability that corre-
lated to patient acuity [5]. Effective mucociliary clearance
is an essential first line of defence to maintaining respira-
tory health [6] and impairment of this clearance may con-
tribute to the risk for pulmonary complications during an
ICU stay.
There are different methods which have been employed to
facilitate pulmonary clearance. Conventional chest pul-
monary therapy (CPT), which consists of manual percus-
sion and or positioning techniques (postural drainage) to
help mobilize and clear mucus is one. Continuous Lateral
Rotational Therapy (CLRT), which consists of alterna-
tively elevating one lung over the other around the
patient's long axis has been shown to help mucus trans-
port [7].
High frequency chest wall oscillation (HFCWO) uses a
pressurized vest to transmit high frequency oscillations to
the chest. This mobilizes secretions which are then cleared
by cough or by suction in the case of intubated patients.
Early trials of HFCWO demonstrated mucus clearance in
dogs [8]. Studies in humans found that HFCWO helps tra-
cheal mucus clearance [9]. This clearance decreases pul-
monary complications in patients with chronic
pulmonary diseases [10,11]. A comparison of clearance in
hospitalized patients demonstrated equivalent efficacy of
CPT and HFCWO [12,13]. Figure 1 shows an intubated
patient being prepared for HFCWO treatment.
Since it was shown that airway clearance would be advan-
tageous for thoracic trauma patients, HFCWO had been
shown to be equivalent to CPT in patients with other
clearance needs, and CPT was tolerated by blunt thoracic
trauma patients, we hypothesized that:
￿ Treatment with HFCWO therapy will result in no signif-
icant changes in physiological parameters in patients with
chest wall injuries (CWI).
￿ There will be no increase in the number of adverse out-
comes related to treatment with HFCWO in patients with
CWI
Methods
This study was approved by the institution's Institutional
Review Board. Patients (18 years or older) with chest wall
injury (blunt or penetrating) admitted to the Hennepin
County Medical Center trauma service (Minneapolis,
Minnesota) with one or more of the following: a) Two or
more rib fractures (unilateral or bilateral); b) Pulmonary
contusion as the result of direct force applied to the lung
documented as an area of increased density or consolida-
tion by chest x-ray; c) Sternal fracture; d) Clavicular or
scapular fracture; e) Spinal cord injury patients (T5 and
above) deemed stable by the neurological staff; f) Hemot-
horax; or g) Pneumothorax requiring one or more chest
tubes were recruited into the study after informed con-
sent. These criteria were documented with chest radio-
graph (CXR), or by chest or neck computerized
tomography (CT) scan. In addition, patients had to have
been admitted within the previous 48 hours. See figure 2
for a flow diagram.
Intubated patient being fitted for HFCWO treatment Figure 1
Intubated patient being fitted for HFCWO treat-
ment. The vest type being fitted is the "wrap type" of vest. 
This allows for positioning of the vest so it does not interfere 
with chest tubes or lines.
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Flow Chart showing patient selection and exclusion Figure 2
Flow Chart showing patient selection and exclusion. A total of 38 patients were screened. Of these, 28 patients met 
criteria. Twenty-five patients consented but four did not complete the therapy course. Twenty one patients were evaluated 
and followed-up for evaluation of HFCWO treatment. As an observational pilot safety study, power calculations for the 
number of patients to be enrolled were not done. The target of 25 patients was arbitrary.
Blunt Thoracic Trauma Patients Admitted to 
HCMC, 38 screened 
 
inclusion criteria 
1.  Subject admitted within last 48 hours 
2.  Subject has blunt or penetrating chest wall injury, with one or more of: 
a.  2 or more rib fractures 
b. Pulmonary  contusion 
c. Sternal  fracture 
d.  Clavicular or scapular fracture 
e.  SCI pts (T5 and above) deemed stable 
f.  Trauma/thoracic surgery pts. >= 24 hrs post-op. 
g. Hemothorax 
h.  Pneumothorax w/ 1 or more chest tubes 
3.  Subject 18 years or older 
4. Subject or Subject Family informed on study and signed subject consent
Meet criteria 
 
Exclusion criteria 
1.  Subject have Glasco Coma Scale (GCS) score <= 13 @ 24 – 48 hrs. and no 
intracranial pressure monitoring? 
2. Pregnant? 
3.  Less than 18 years old? 
4.  Unstable spinal injury? 
5.  Active hemoptysis and hemodynamic instability? 
6.  ICP > 20 mm Hg? 
7.  CPP of < 70? 
8.  Unstable pelvic fracture requiring Mast trousers or towel wrap which 
prevents rolling of patient? 
4 patients drop-out. Final n = 21 patients
Pts. meet inclusion, not exclusion criteria and sign 
informed consent 
(n = 25)
28 patients meet criteria, 25 
patients consent Journal of Trauma Management & Outcomes 2008, 2:8 http://www.traumamanagement.org/content/2/1/8
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Since this was a safety study and not a controlled compar-
ison, power calculations were not performed. The selec-
tion of 25 patients was empirical. Only the actual number
of patients enrolled was recorded. The total number
screened was not documented.
The first twenty-five eligible patients to consent were
enrolled in the study over approximately 10 months. Each
patient was prescribed 2, 15 minute HFCWO treatments
per day using The Vest® Airway Clearance System (Hill-
Rom, Inc., St Paul, MN). The Vest® system was set to a fre-
quency of 10–12 Hz and a pressure of 2–3 (arbitrary
unit). Physiological parameters were measured before,
during, and after treatment. These parameters were: incen-
tive spirometry; heart rate; heart rhythm; respiratory rate;
mean arterial pressure calculated from systolic and diasto-
lic blood pressure; O2 saturation (SpO2); and in selected
cases, intra-cranial pressure. For those patients receiving
mechanical ventilation, the following ventilator settings
were documented: ventilation mode; ventilation rate;
PEEP; pressure support level; delivered tidal volume;
FiO2; peak pressure. All treatments were offered to the
patients, but some were skipped according to the patient's
wishes (16 total treatments skipped due to pain, 7 treat-
ments due to nausea) or early discharge (25 treatments).
Because of inconsistencies in recording the "during treat-
ment" parameters, only the before and after treatment
parameters were compared. Student's t-test for paired val-
ues was used and values were considered significant at a p
value of 0.05. All patients were followed-up after 30 days
to determine: subject health status, number of hospital
days required, number of ICU days required, number of
days on mechanical ventilation (if applicable), incidence
of re-intubation (if applicable), hospital re-admissions for
pulmonary complications, and subject assessment of
HFCWO therapy (comfort/tolerance).
Results
Twenty-five patients were initially enrolled. Four with-
drew prior to the completion of the study. None withdrew
as a result of adverse effects of the HFCWO treatment.
Table 1 presents the age and sex of the patients who
remained in the study, the type of trauma injuries and the
adjunct equipment at the time of HFCWO treatment.
None of the equipment was dislodged or compromised in
function by the HFCWO treatment. The majority of
trauma was the result of motor vehicle accidents but also
included 3 falls, 1 industrial accident, and 1 gunshot
wound to the chest.
Seven patients initially admitted with small pneumotho-
races were treated conservatively; none of these patients
required tube thoracostomy after HFCWO. In patients
with chest tubes (n = 11), mean chest tube output during
treatment and the 30 minutes following was 10 cc (range
0–50 cc). One patient with flail chest and a large pleural
effusion required chest tube placement after the first
HFCWO treatment due to increasing serous pleural fluid;
treatments were continued without further incident.
None of the ten patients with solid organ injury being
managed non-operatively required transfusion or opera-
tive management. Use of HFCWO did not result in
Table 1: Patient demographics, diagnoses, and adjunctive equipment present during HFCWO therapy
Patient # Age Gender Injuries Adjunct equipment
01 39 M rib fract, scapular fract, pneumothorax, h None
02 68 M rib fract, clavicle fract, stab spinal cord fract, pneumothorax chest tube
04 40 F pulm contusion other line
05 48 M rib fract other line
06 18 F rib fract, pulm contusion, clavicle fract, scapular fract, pneumothorax other line
07 19 M rib fract, pulm contusion, clavicle fract, pneumothorax chest tube, DS, other line
09 62 M pneumothorax chest tube, other line
10 44 F rib fract other line
11 26 M rib fract, pneumothorax chest tube, other line
12 39 M rib fract, sternal fracture, pneumothorax chest tube, other line
13 68 M rib fract, liver laceration, kidney laceration, pneumothorax other line
14 70 M rib fract, pneumothorax chest tube, other line
15 44 F rib fract, pulm contusion, pneumothorax other line
16 49 F rib fract, pulm contusion, pneumothorax chest tube, other line
19 44 M rib fract, pulm contusion other line
20 21 M rib fract, clavicle fract, stab spinal cord fract other line
21 59 M rib fract, pneumothorax, intraperitoneal hemorrhage other line
22 42 F rib fract, pulm contusion, hemothorax, pneumothorax other line
23 51 M pulm contusion, hemothorax chest tube, other line
24 70 M rib fract, pulm contusion, pneumothorax chest tube, other line
25 44 F rib fract, hemothorax, pneumothorax, kidney laceration chest tube, other lineJournal of Trauma Management & Outcomes 2008, 2:8 http://www.traumamanagement.org/content/2/1/8
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increased bleeding or need for surgical treatment of solid
organ injury in those subjects that were not scheduled for
surgery.
Table 2 presents the results of physiologic parameters
measured before and after HFCWO treatment. Heart
rhythm is not included as there were no remarkable
changes pre and post treatment. Mean arterial pressure
was measured for some time points for some of the
patients (data not shown). None were significantly differ-
ent than the pre- or post-treatment values. The mean
number of treatments each patient received was 7.7.
The 30 day follow-up survey revealed no deaths or hospi-
tal re-admissions. Two patients required re-intubation.
One of them was diagnosed with pneumonia. Patient 24
was intubated and heavily sedated during the HFCWO
treatment and did not remember the therapy. The other
patients were asked about their experience with the Vest.
Their responses are shown in Table 3. Seventy-five percent
experienced mild or no pain due to the Vest therapy itself.
Seventy percent felt the therapy made their breathing bet-
ter. Seventy-five percent felt the treatment improved their
cough and seventy percent would recommend this ther-
apy.
Discussion
This study was undertaken to see if HFCWO would be safe
and tolerated by patients with blunt chest wall trauma.
Studies have shown that HFCWO can aid in the process of
airway clearance for hospitalized patients with or without
ventilator support [12,13]. The patients in this study tol-
erated the therapy well and typically did not require addi-
tional medication for pain management, despite the
severity of their injuries. There were no lines, chest tubes,
drains or epidural/ventriculostomy catheters dislodged.
Maintaining pulmonary function in the compromised
critically ill patient is challenging. Patients with thoracic
trauma are compromised mechanically so that ancillary
methods such as mechanical ventilation are often
required. However, numerous studies have shown that
ventilator-associated pneumonia (VAP) rates can be as
high as 65% [14]. Pulmonary clearance is important to
prevent VAP, but critical illness impairs the function of the
normal mechanisms [5]. Bacterial infections both disrupt
the ciliary beat frequency [15] and induce the release of
inflammatory components which in turn causes mucus
production [16-20]. It is well documented that HFCWO is
efficacious for pulmonary clearance in CF patients [21,22]
so it is reasonable to try HFCWO for clearance in other
conditions.
The overall care of the thoracic trauma ICU patient may be
improved by the addition of airway clearance modalities.
However, the safety of the device when used by the blunt
trauma patient had not been previously demonstrated.
The thirty day follow up was an arbitrary time. The inten-
tion was to query the patients after significant healing in
order to get a more objective opinion of their response to
the therapy.
One of the limitations of the study is the lack of documen-
tation of the conditions of the patients who did not par-
ticipate. It is possible that they represented an overall
more seriously injured group which would not find the
treatment as tolerable as the included patients. Another
limitation is the lack of randomization to conventional
CPT or HFCWO therapy. It is not known if the results
would be weighted toward one method or the other.
However, we felt it was crucial to know that the Vest treat-
ment would be tolerated and as safe as CPT.
The results presented here demonstrate that HFCWO ther-
apy is well tolerated by patients with blunt thoracic
Table 2: Physiological parameters measured before and after HFCWO (Vest) treatment
Parameter Before Tx Mean (SD) (95% CI) After Tx Mean (SD) (95% CI) P value
Incentive Spirometry (cc) 1330.8 (582.0)
(166.8 – 2502.8)
1349.8 (544.7)
(260.4 – 2439.2)
0.81
Respiratory Rate (bpm) 18.1 (4.0)
(10.1 – 26.1)
18.1 (3.9)
(10.3 – 25.9)
0.95
Heart Rate (bpm) 91.4 (16.6)
(58.2 – 124.6)
91.0 (15.9)
(59.2 – 122.8)
0.80
Systolic BP (mm Hg) 131.1 (16.9)
(97.3 – 164.9)
128.9 (16.7)
(95.5 – 162.3)
0.24
Diastolic BP (mm Hg) 70.1 (12.5)
(45.1 – 95.1)
68.3 (12.9)
(42.4 – 94.1)
0.21
MAP 90.4 (12.5)
(65.4 – 115.4)
88.6 (12.7)
(63.2 – 114)
0.20
SaO2 (%) 95.9 (2.7)
(90.5 – 101.3)
95.9 (2.7)
90.5 – 101.3)
0.85J
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Table 3: Patient survey results
Describe the pain you experienced during Vest therapy How do you feel overall this therapy made your breathing? Did the vest therapy improve your cough? Would you recommend this therapy?
ID None Mild Moderate Severe Better Worse No Change Yes No No Change Yes No Unsure
0001 X X X X
0002 X X XX
0004 X XX X
0005 X X X X
0006 X X X X
0007 X X X X
0009 X XX X
0010 X X X X
0011 X X X X
0012 X X X X
0013 X X X X
0014 X X X X
0015 X XX X
0016 X X X X
0019 X X X X
0021 X X X X
0022 X XX X
0023 X X X X
0025 X X X X
Sum 4 10 5 14 0 6 15 3 2 14 2 4
%2 0 5 0 2 5 0 7 0 0 3 0 7 5 1 5 1 0 7 0 1 0 2 0Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Trauma Management & Outcomes 2008, 2:8 http://www.traumamanagement.org/content/2/1/8
Page 7 of 7
(page number not for citation purposes)
trauma and support additional studies to see if the airway
clearance capabilities of HFCWO add to the successful
treatment of thoracic trauma patients. If so, this method
will add another tool to free-up the provider of manual
CPT for other patients. It will also add a consistent, tech-
nique independent therapy which can be modified (pres-
sure, frequency, and duration) to best accommodate a
patients needs.
Conclusion
This study suggests that HFCWO treatment is safe for
trauma patients with lung and chest wall injuries. These
findings support further work to demonstrate the airway
clearance benefits of HFCWO treatment.
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